Physician profile
Patrick Neshiwat
NPI 1477173441
$744.96
in general payments reported to CMS, 2019-2025
13 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $46.51 · 2024: $452 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.14 |
| Education | $124.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $145.75 | 2024 | Ozempic, Wegovy |
| Spr Therapeutics, INC | $141.40 | 2024 | Sprint Pns System |
| Exact Sciences Corporation | $125.00 | 2025 | Cologuard Collection Kit |
| Abiomed | $69.69 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $42.52 | 2024-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $36.79 | 2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $34.49 | 2024 | Arcalyst |
| Ironwood Pharmaceuticals, INC | $28.93 | 2024 | |
| Tandem Diabetes Care, INC. | $27.94 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $25.66 | 2024 | |
| Corium, LLC | $24.34 | 2023 | Adlarity |
| Pfizer INC. | $22.17 | 2023 | |
| Lilly USA, LLC | $20.28 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Neshiwat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.